Overexpression of RAD51 occurs in aggressive prostatic cancer

Histopathology

Volumn 55, Issue 6, 2009, Pages 696-704

  Mitra, Anita ^a   Jameson, Charles ^b   Barbachano, Yolanda ^c   Sanchez, Lydia ^d   Kote Jarai, Zsofia ^a   Peock, Susan ^e   Sodha, Nayanta ^a   Bancroft, Elizabeth ^a   Fletcher, Anne ^a   Cooper, Colin ^a   Easton, Douglas ^e   Eeles, Rosalind ^a   Foster, Christopher S ^f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Institute of Cancer Research ^*

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Structural Biology and Biocomputing Programme   (Spain)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

BRCA1 and BRCA1 mutation carriers; Prostatic cancer; RAD51 immunohistochemistry

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RAD51 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL COUNT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RAD51 RECOMBINASE; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 70849105068     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03448.x     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 2008 58 71 96.
2. Cancer Research UK. Cancer stats, key facts on prostate cancer - November 2008. Available at http://www.cancerresearchuk.org/cancerstats/types/ prostatecancer Last accessed April 2009.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global science statistics. CA Cancer J. Clin. 2005 55 74 108.
4. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet. 2008 17 R109 R115.
5. Al Olama AA, Kote-Jarai Z, Giles GG et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 2009 41 1058 1060.
6. Eeles RA, Kote-Jarai Z, Al-Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 2009 41 1116 1121.
7. Mitra A, Fisher C, Foster CS et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 2008 98 502 507.
8. Edwards SM, Kote-Jarai Z, Meitz J et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 2003 72 1 12.
9. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 2002 94 1358 1365. (Pubitemid 35154140)
10. BCLC. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 1999 91 1310 1316.
11. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J. Natl Cancer Inst. 2007 99 929 935.
12. Scully R, Chen J, Plug A et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997 88 265 275. (Pubitemid 28015875)
13. Jin Y, Xu XL, Yang MC et al. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc. Natl Acad. Sci. USA 1997 94 12075 12080.
14. Scully R, Chen J, Ochs RL et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997 90 425 435.
15. Tarsounas M, Davies D, West SC. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 2003 22 1115 1123.
16. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol. 2004 24 9305 9316.
17. Fernandez-Ramires R, Sole X, De Cecco L et al. Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. Br. J. Cancer 2009 101 1469 1480.
18. Jhavar S, Corbishley CM, Dearnaley D et al. Construction of tissue microarrays from prostate needle biopsy specimens. Br. J. Cancer 2005 93 478 482.
19. Berney DM, Fisher G, Kattan MW et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int. 2007 100 1240 1244.
20. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J. Pathol. 1994 173 371 379.
21. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 1987 8 138 140.
22. Qiao GB, Wu YL, Yang XN et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 2005 93 137 143.
23. Maacke H, Opitz S, Jost K et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 2000 88 907 913.
24. Antoniou AC, Cunningham AP, Peto J et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer 2008 98 1457 1466.
25. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int. J. Oncol. 2006 28 1113 1119.
26. Maacke H, Jost K, Opitz S et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000 19 2791 2795.
27. Gildemeister OS, Sage JM, Knight KL. Cellular redistribution of Rad51 in response to DNA damage: a novel role for Rad51C. J. Biol. Chem. 2009 284 31945 31952.
28. Zhang J, Ma Z, Treszezamsky A, Powell SN. MDC1 interacts with Rad51 and facilitates homologous recombination. Nat. Struct. Mol. Biol. 2005 12 902 909.
29. Dominguez-Bendala J, Priddle H, Clarke A, McWhir J. Elevated expression of exogenous Rad51 leads to identical increases in gene-targeting frequency in murine embryonic stem (ES) cells with both functional and dysfunctional p53 genes. Exp. Cell Biol. 2003 286 298 307.
30. Sorensen CS, Hansen LT, Dziegielewski J et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005 7 195 201.
31. Conilleau S, Takizawa Y, Tachiwana H, Fleury F, Kurumizaka H, Takahashi M. Location of tyrosine 315, a target for phosphorylation by cAbl tyrosine kinase, at the edge of the subunit-subunit interface of the human Rad51 filament. J. Mol. Biol. 2004 339 797 804.
32. Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur. J. Gynaecol. Oncol. 2005 26 589 598.
33. Bennett BT, Knight KL. Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51. J. Cell. Biochem. 2005 96 1095 1099.
34. Friedler A, Veprintsev DB, Rutherford T, von Glos KI, Fersht AR. Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J. Biol. Chem. 2005 280 8051 8059.
35. Junttila MR, Gerard IE. p53 - a Jack of all trades but master of none. Nat. Rev. Cancer 2009 9 821 829.
36. Kudahetti S, Fisher G, Ambroisine L et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int. 2009 104 20 24.
37. Mitra A, Jameson C, Barbachano Y et al. Overexpression of TP53 is associated with aggressive prostate cancer but does not distinguish disease in BRCA1 or BRCA2 mutation carriers from a control group. Open Prostate Cancer J. 2009 2 38 45.
38. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum. Mutat. 2006 27 14 20.
39. Dong JT. Prevalent mutations in prostate cancer. J. Cell. Biochem. 2006 97 433 447.
40. Gumerlock PH, Chi SG, Shi XB et al. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J. Natl Cancer Inst. 1997 89 66 71.
41. Honrado E, Osorio A, Palacios J et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiates BRCA2-associated tumors. J. Clin. Oncol. 2005 23 7503 7511.
42. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 1999 59 3547 3551. (Pubitemid 29381849)
43. Godthelp BC, Artwert F, Joenje H, Zdzienicka MZ. Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1. Oncogene 2002 21 5002 5005.
44. Coppola V, de Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr. Relat. Cancer. 2009 Sep 24 Epub ahead of print C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004 23 546 553.
45. Grindedal EM, Moller P, Eeles R et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2009 18 2460 2467.